

Curriculum Vitae

Peter Paul Ventre, M.D.

Professional Experience

2025 - Present	Chief Psychiatric Officer and Founder NextPhase Research Florida Hollywood, FL
2021 - Present	Founder & Chief Medical Officer Crestview Recovery Center Asheville, NC
2017 - Present	Founder & Chief Medical Officer Dreamlife Recovery Donegal, PA
2011 - Present	Founder & Chief Executive Officer My Psychiatrist, Ventre Medical Associates, LLC Hollywood, FL
2018 - 2022	Principal Investigator & President CenExel Research Centers of America Hollywood, FL
2014 - 2019	Principal Investigator, Chief Executive Officer & President CenExel Research Centers of America Oakland Park, FL
2011 - 2018	Chief of Psychiatry Broward Health Medical Center Fort Lauderdale, FL
2008 - 2011	Principal Investigator Behavioral Clinical Research, Inc. Lauderhill, FL
2008 - 2011	Principal Investigator Sleep Disorder Solutions, Inc. Miami, FL
2008 - 2011	Sub-Investigator Fidelity Clinical Research, Inc. Lauderhill, FL
2008 - 2010	Psychiatrist Compass Health Systems, PA Miami, FL

Education

2007 - 2008	Residency in Psychiatry
-------------	-------------------------

University of Florida College of Medicine
Gainesville, FL 32603

2005 - 2007 Residency in Psychiatry
Cabrini Medical Center, Mount Sinai School of Medicine
New York, NY

2004 - 2005 Internship in Internal Medicine
Cabrini Medical Center, Mount Sinai School of Medicine
New York, NY

1999 - 2001 Doctor of Medicine
Universidad Iberoamericana,
Santo Domingo, Dominican Republic

1997 - 1999 Doctor of Medicine
San Juan Bautista School of Medicine
Caguas, Puerto Rico

1992 - 1996 Bachelor of Science
Biology and General Science, University of Puerto Rico
Rio Piedras, Puerto Rico

Certifications

Psychiatry Board Certified by ABPN, Certification Number: 400-35-31-137

Diplomate of the American Board of Psychiatry & Neurology

Past Research Affiliation

CenExel Research Centers of America at
Fort Lauderdale Behavioral Health Center
5757 N. Dixie Hwy
Oakland Park, FL 33334

CenExel Research Centers of America
7261 Sheridan Street, Suite 210
Hollywood, FL 33024

Professional Licensure

State of Florida Medical Doctor
ME 103007

State of Florida DEA
Registration FV4508505 / FV1117793

Affiliations

Dreamlife Recovery

Crestview Recovery

Broward Health Medical Center, Broward Health Imperial Point, Broward Health North

Society Memberships

Association of Clinical Research Professionals

American Psychiatric Association

Florida Psychiatric Association

Stanford Latino Entrepreneurship Initiative

Rater Certifications and Scales Experience

Abnormal Involuntary Movement Scale (AIMS)

Barnes Akathisia Rating Scale (BAS)

Brief Psychiatric Rating Scale (BPRS)

Calgary Depression Scale for Schizophrenia (CDSS)

Children's Depression Rating Scale (CDRS)

Clinical Global Impression Severity/Improvement (CGI-S/I)

Clinician's Interview Based Impression of Change (CIBIC)

Clinical Opiate Withdrawal Scale (COWS)

Columbia Suicide Severity Rating Scale (C-SSRS)

Extrapyramidal Symptom Rating Scale (ESRS)

Global Assessment of Functioning (GAF)

Global Assessment Scale (GAS)

Hamilton Anxiety Rating Scale (HAM-A)

Hamilton Depression Rating Scale (HAM-D)

Inventory of Depressive Symptomatology-30 (IDS-30)

Kiddie - Positive and Negative Syndrome Scale (Kiddie PANSS)

Kiddie - Schedule for Affective Disorders and Schizophrenia (K-SADS)

Mini International Neuropsychiatric Interview (MINI/MINI-Kid)

Mini-Mental State Examination (MMSE)

Modified Himmelsbach Opioid Withdrawal Scale (MHOWS)

Montgomery-Asberg Depression Rating Scale (MADRS)

Negative Symptoms Assessment-16 (NSA-16)

Personal and Social Performance Scale (PSP)

Positive and Negative Syndrome Scale (PANSS)

Schedule for Affective Disorders and Schizophrenia - Change (SADS-C)

Simpson-Angus Scale (SAS)

Structured Clinical Interview for DSM-IV Axis I Disorder (SCID)

Young Mania Rating Scale (YMRS)

Clinical Research Experience

2022: Double-blind, placebo-controlled, randomized withdrawal study to evaluate XXXX physical dependence in adult subjects with schizophrenia.

2022: Phase 3, randomized, 28-day, double-blind, placebo-controlled, multicenter study to assess the safety and efficacy of XXXX in subjects with acute exacerbation of schizophrenia trial, followed by a 52-week open-label extension.

2021: Phase 3, randomized, observer-blind study to evaluate the lot consistency, safety, tolerability, and immunogenicity of the vaccine XXXX against COVID-19 in healthy adults 18 through 55 years of age.

2021: Randomized, single-blind, two-period crossover to investigate the effect of XXXX on the Pharmacokinetics of Metformin in subjects with schizophrenia.

2021: Two-part Phase 2 study to assess the efficacy, safety, and tolerability of XXXX administered to adults with major depressive disorder at imminent risk of suicide.

2021: Double-blind, placebo-controlled, randomized dose-ranging trial to investigate efficacy and safety of intravenous XXXX infusion in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder in subjects who have suicidal ideation with intent.

2021: Randomized, double-blind, placebo-controlled, parallel-group study of XXXX for the prevention of relapse in patients with schizophrenia.

2021: Randomized, double-blind (patient, investigator), placebo-controlled, dose-escalation study on safety, tolerability, pharmacokinetic and preliminary efficacy of XXXX as adjunctive therapy in patients with major depressive disorder after single oral dosing.

2020: Phase 1, open-label, randomized, single ascending dose trial to determine the pharmacokinetics, safety, and tolerability of XXXX long acting injectable in adult subjects with schizophrenia.

2020: Phase 1, open-label, randomized, single ascending dose trial to determine the pharmacokinetics, safety, and tolerability of XXXX long acting injectable in adult subjects with schizophrenia.

2020: Randomized, subject and investigator-blinded, placebo controlled, cross-over, multi-center Proof of Concept (PoC) study to assess the wakefulness promoting effect, safety, tolerability, and pharmacokinetics of XXXX in shift work disorder (SWD) patients.

2020: Phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of sars-cov-2 XXXX vaccine candidates against covid-19 in healthy individuals.

2020: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of iloperidone for 4 weeks in the treatment of patients with acute manic episodes associated with Bipolar I Disorder.

2020: Phase 2B placebo/active-controlled XXXX in schizophrenia.

2020: Open-label extension study to assess the long-term safety, tolerability and efficacy of XXXX in subjects with DSM-5 schizophrenia.

2020: Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the efficacy and safety of XXXX in acutely psychotic hospitalized adults with DSM-5 schizophrenia.

2019: XXXX in acutely psychotic schizophrenia patients.

2019: Non-alcoholic fatty liver disease study of XXXX + XXXX.

2019: Acute suicidal ideation in bipolar depression study.

2019: Major depressive disorder trial of XXXX.

2019: Lot consistency trial of XXXX for anthrax prophylaxis.

2018: 20-valent pneumococcal vaccine trial in adults.

2018: Phase 3 Clostridium difficile vaccine safety/immunogenicity study.

2018: Adjunctive XXXX extension study in treatment-resistant MDD.

2018: Bipolar I relapse prevention study using dose-reduction of XXXX.

2018: Schizophrenia relapse prevention with XXXX dose-reduction.

2018: Zika virus IgM assay evaluation.

2018: Generic vs. reference XXXX PK trial in schizophrenia.

2018: Shift work disorder proof-of-concept study of XXXX.

2018: Polysomnography study of XXXX in insomnia.

2018: Rapid treatment study of XXXX in MDD with suicidality.

2018: Monotherapy trial of XXXX in MDD.

2018: XXXX in acute suicidal ideation in bipolar depression.

2018: Acute mania study of XXXX in bipolar I disorder.

2018: Open-label safety of XXXX in bipolar I disorder.

2018: Dose-reduction paradigm of XXXX in bipolar I relapse prevention.

2017: Rapastinel adjunctive therapy in MDD.

2017: 12-week placebo-controlled XXXX in schizophrenia negative symptoms.

2017: Buprenorphine-transition study using XXXX.

2017: Open-label safety study of XXXX in schizophrenia.

2017: Risperidone-controlled study of XXXX in acute schizophrenia.

2017: Add-on DAO inhibitor XXXX in schizophrenia.

2017: XXXX in jet-lag type insomnia.

2017: Adjunctive XXXX in treatment-resistant MDD.

2017: Relapse prevention in MDD with XXXX.

2017: Oral XXXX for mild-to-moderate Alzheimer's.

2016: Weight gain comparison of XXXX vs. Olanzapine.

2016: Long-term schizophrenia safety study of XXXX.

2016: Long-term safety study of adjunctive XXXX in MDD.

2016: Adjunctive XXXX for MDD relapse prevention.

2016: Fixed-dose trial of XXXX in bipolar depression.

2016: Extension safety study of XXXX in Alzheimer's agitation.

2016: XXXX in agitation related to Alzheimer's disease.

2015: Long-term safety study of XXXX in opioid use disorder.

2015: Environmental/socioeconomic factors in opioid remission.

2015: Subcutaneous XXXX injections in opioid use disorder.

2015: Dose escalation trial for XXXX in alcohol use disorder.

2015: XXXX with buprenorphine in opioid use disorder.

2015: PK study of XXXX in stable schizophrenia.

2015: Open-label extension of XXXX in fibromyalgia-related pain.

2015: Non-interventional follow-up to adjunctive MDD treatment study.

2015: Study of extended-release XXXX in GAD.

2014: XXXX study in schizophrenia with alcohol use disorder.

2014: Study of XXXX in adult females with MDD.

2014: Long-term safety study of adjunctive XXXX in MDD.

2014: Phase 3 efficacy/safety trial of adjunctive XXXX in MDD.

2013: Pharmacokinetics of XXXX injection in schizophrenia.

2013: Extension study of XXXX in schizophrenia.

2013: Dose-ranging study of XXXX in schizophrenia.

2013: Pro-cognitive adjunctive XXXX treatment in schizophrenia.

2013: Open-label adjunctive XXXX trial in early-episode schizophrenia.

2013: Evaluation of XXXX in adolescent MDD.

2013: Phase 2a PoC trial of XXXX in MDD patients.

2013: Long-term safety study of adjunctive XXXX in MDD.

2013: Phase 2 adjunctive maintenance treatment in bipolar I disorder.

2013: Proof-of-concept trial for XXXX in autism spectrum disorder.

2013: Safety extension for Alzheimer's agitation/aggression study.

2013: Agitation/aggression treatment study in moderate-to-severe Alzheimer's disease.

2012: Tardive dyskinesia study with XXXX in schizophrenia or schizoaffective disorder.

2012: Relapse prevention study of XXXX in schizophrenia (26-week DB, 52-week OL).

2012: Long-term analgesic safety study of XXXX in chronic pain patients.

2012: Flexible-dose adjunctive XXXX for partial SSRI responders with MDD.

2012: Flexible-dose study of XXXX as adjunctive therapy in MDD.

2012: Maintenance treatment trial of XXXX in bipolar I disorder.

2012: Sublingual tablet study of XXXX as adjunctive treatment in bipolar I depression.

2012: Maintenance treatment study using IM depot formulation of XXXX in bipolar I disorder.

2012: Randomized withdrawal study of XXXX in pediatric autism spectrum disorders.

2012: Open-label safety study of XXXX in pediatric autism spectrum disorders.

2012: Placebo-controlled study of XXXX in generalized anxiety disorder.

2012: Placebo-controlled study on XXXX in adults with ADHD.

2011: Six-month open-label re-treatment study of XXXX in opioid addiction.

2011: Phase IIIb trial evaluating time to relapse in schizoaffective disorder with XXXX.

2011: Open-label study assessing hospitalization rates in schizophrenia patients treated with XXXX IM depot.

2010: Placebo- and active-controlled trial of XXXX in opioid dependence.

2010: Long-term study of XXXX vs. standard of care in schizophrenia.

2010: Comparator study of XXXX in schizophrenia patients.

2010: Study of XXXX in schizophrenia patients with predominant negative symptoms on stable atypical antipsychotics.

2010: Phase II study on XXXX doses vs. placebo in schizophrenia patients.

2010: 12-week, placebo-controlled study of XXXX in sub-optimally controlled schizophrenia symptoms.

2010: Study of XXXX in treatment-resistant major depression.

2010: XXXX vs. placebo in patients with depression and painful physical symptoms.

2010: XXXX vs. placebo in children/adolescents with major depressive disorder.

2010: Worldwide, open-label trial to examine long-term safety of XXXX in pediatric migraine patients.

2010: Placebo-controlled trial evaluating XXXX in pediatric and adolescent migraine (ages 6–17).

2010: Short-term randomized withdrawal study of XXXX in DSM-IV-TR schizophrenia.

2010: 24-week, placebo-controlled study of XXXX for persistent negative symptoms of schizophrenia.

2010: Phase IV, international, longitudinal study on individuals with ADHD.

2010: Study of XXXX in children/adolescents with ADHD (6 to 18 years).

2010: Effect of anti-amyloid beta monoclonal antibody XXXX on Alzheimer's progression.

2010: Evaluation of XXXX in agitation/psychosis in Alzheimer's patients.

2010: Bayesian adaptive design study of XXXX in mild-to-moderate Alzheimer's on stable AChEI therapy.

2010: Flexible-dose study of XXXX in bipolar I depression.

2010: Adjunctive XXXX for major depression in bipolar I disorder.

2009: Long-term, open-label safety study of XXXX in children and adolescents with ADHD-associated insomnia.

2009: Phase IV, double-blind, placebo-controlled withdrawal study of XXXX in adults aged 18–55 with ADHD.

2009: Study of XXXX in elderly subjects with psychosis and behavioral disturbances related to Alzheimer's disease.

2009: Multi-center, placebo-controlled, double-blind, phase II study on XXXX in generalized anxiety disorder (GAD).

2009: Study assessing efficacy and safety of XXXX and XXXX combination therapy for bipolar I disorder in adolescents.

2009: Study evaluating poor metabolizer prevalence among depression patients treated with XXXX.

2009: Double-blind, placebo-controlled, fixed-dose study on XXXX in adult outpatients with major depressive disorder.

2009: Study comparing XXXX versus placebo in elderly patients with major depressive disorder.

2009: 52-week, open-label study of XXXX as maintenance treatment in schizophrenia.

2008: Phase III evaluation of the efficacy and safety of [HCl sustained-release] as add-on to psychostimulant medication vs. psychostimulant medication alone in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD).

2008: Open-label chronic exposure evaluation of the safety of XXXX [HCl sustained-release] in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD).

2008: Controlled trial on safety and efficacy of XXXX versus placebo in patients with bipolar depression.

2008: Controlled trial on XXXX versus placebo in patients with bipolar disorder in manic or mixed states.

2008: 52-week, open-label extension trial evaluating XXXX in chronic primary insomnia who completed clinical trial XXXX.

2008: 24-week, double-blind, placebo-controlled, parallel-group, fixed-dosage study of XXXX as adjunctive therapy in schizophrenia-related cognitive impairment.

2008: Multi-center, double-blind, randomized, placebo-controlled study of long-term efficacy, safety, and tolerability of an intramuscular depot formulation of XXXX in patients with schizophrenia.

2008: Randomized, active-comparator controlled, long-term study of XXXX in schizophrenia/schizoaffective disorder.

2008: Double-blind, randomized, placebo-controlled, multi-center study on the efficacy, safety, and tolerability of XXXX in adults with ADHD.

2000: Correlative study on obesity and diabetes associated with diet and exercise.

1996: Study of Proto-oncogene P53 in Rats, using DNA probes and sampling.